# EDGAR Filing Document

**Accession Number:** 0001396814
**File Stem:** 0001209191-23-021396
**Filing Date:** 2023-3
**Character Count:** 9953
**Document Hash:** df0454458f7dd2fed74f71ecd065a333
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-021396.hdr.sgml**: 20230328

**ACCESSION NUMBER**: 0001209191-23-021396

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230314

**FILED AS OF DATE**: 20230328

**DATE AS OF CHANGE**: 20230328

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Ellis Ronald J. Jr.
- **CENTRAL INDEX KEY:** 0001790670

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35060
- **FILM NUMBER:** 23769776

**MAIL ADDRESS:**
- **STREET 1:** C/O TELA BIO, INC.
- **STREET 2:** 1 GREAT VALLEY PARKWAY, SUITE 24
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pacira BioSciences, Inc.
- **CENTRAL INDEX KEY:** 0001396814
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 510619477
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 5401 WEST KENNEDY BOULEVARD
- **STREET 2:** SUITE 890
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33609
- **BUSINESS PHONE:** 813-553-6680

**MAIL ADDRESS:**
- **STREET 1:** 5 SYLVAN WAY
- **STREET 2:** SUITE 300
- **CITY:** PARSIPPANY
- **STATE:** NJ
- **ZIP:** 07054

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Pacira Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20101029

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PACIRA INC
- **DATE OF NAME CHANGE:** 20080318

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Blue Acquisition Corp
- **DATE OF NAME CHANGE:** 20070418

## Ex-24

```
<PRE>
POWER OF ATTORNEY

	I, Ronald Ellis, hereby authorize and designate each of Charles A. Reinhart,
III, Kristen Williams and Ned Prusse, signing singly, as my true and lawful
attorney-in-fact to:

		(1)	execute for and on my behalf, in my capacity as an officer and/or director
of Pacira BioSciences, Inc. and its affiliates (the "Company"), the Form ID and
Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), and the rules and regulations
promulgated thereunder;

		(2)	do and perform any and all acts for and on my behalf which may be
necessary or desirable to complete and execute any such Form ID or Form 3, 4 or
5 and timely file such form with the Securities and Exchange Commission, any
stock exchange or similar authority; and

		(3)	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney in fact, may be to my benefit,
in my best interest, or legally required of me, it being understood that the
statements executed by such attorney in fact on my behalf pursuant to this Power
of Attorney shall be in such form and shall contain such terms and conditions as
such attorney in fact may approve in such attorney in fact's discretion.

	I hereby further grant to each such attorney in fact full power and authority
to do and perform any and every act and thing whatsoever requisite, necessary,
or proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as I might or could do if
personally present, with full power of substitutes or revocation, hereby
ratifying and confirming all that such attorney in fact, or such attorney in
fact's substitute or substitutes, shall lawfully do or cause to be done by
virtue of this Power of Attorney and the rights and powers herein granted.  I
hereby acknowledge that the foregoing attorneys in fact, in serving in such
capacity at my request, are not assuming, nor is the Company assuming, any of my
responsibilities to comply with Section 16 of the Exchange Act.

	This Power of Attorney shall remain in full force and effect until I am no
longer required to file the Form ID or Forms 3, 4 and 5 with respect to my
holdings of and transactions in securities issued by the Company, unless earlier
revoked by me in a signed writing delivered to the foregoing attorneys in fact.

	IN WITNESS WHEREOF, I have caused this Power of Attorney to be duly executed as
of this 14th day of March, 2023.

	/s/ Ronald Ellis
	Ronald Ellis

</PRE>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Ellis Ronald J. Jr.<br><sub>(Last) (First) (Middle)</sub><br>C/O PACIRA BIOSCIENCES, INC.<br>5401 WEST KENNEDY BOULEVARD, SUITE 890<br><sub>(Street)</sub><br>TAMPA, FL 33609<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Pacira BioSciences, Inc. [ PCRX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-03-14 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Strategy Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 33185<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | <sup>(2)</sup> | 2032-06-08 | Common Stock | 27100 | $59.39 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2031-06-09 | Common Stock | 15000 | $60.96 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2030-06-09 | Common Stock | 22416 | $47.65 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2030-02-04 | Common Stock | 5708 | $43.81 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2029-06-05 | Common Stock | 13866 | $43.54 | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | 2029-01-03 | Common Stock | 12353 | $37.81 | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | 2028-06-13 | Common Stock | 5030 | $38.35 | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | 2027-11-02 | Common Stock | 1554 | $33.05 | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | 2027-06-14 | Common Stock | 660 | $44.20 | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | 2026-11-02 | Common Stock | 3832 | $33.35 | D |  |

---

### Footnotes:

(1) Includes 24,600 unvested restricted stock units. The unvested restricted stock units vest as follows: (i) 11,850 restricted stock units that vest in four equal annual installments on June 3, 2023, June 3, 2024, June 3, 2025 and June 3, 2026, (ii) 4,500 restricted stock units that vest in three equal annual installments on June 3, 2023, June 3, 2024 and June 3, 2025, (iii) 7,000 restricted stock units that vest in two equal annual installments on June 3, 2023 and June 3, 2024 and (iv) 1,250 restricted stock units that vest on June 3, 2023, in each case, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

(2) The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

(3) The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

(4) The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.

**Signature:** /s/ Kristen Williams, Attorney-in-Fact  
**Date:** 2023-03-28

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**